Background: Prediction, risk assessment, and diagnosis of autoimmune diseases often rely on detection of autoantibodies directed to multiple target antigens, such as the 65-kDa isoform of glutamic acid decarboxylase (GAD65-abs) and the tyrosine phosphatase-like protein islet antigen-2 (IA2-abs), the two major subspecificities of islet cell antibodies (ICAs) associated with insulindependent diabetes mellitus. We hypothesized that a combination of autoantigens in a fusion protein unifying the important immunodominant epitopes could provide an efficient target for cost-effective, one-step screening of sera. Methods: Chimeric proteins composed of GAD65 and IA2 residues were constructed, analyzed for their immune reactivity with monoclonal antibodies and sera, and used in a diagnostic assay with 35 S-labeled protein as antigen. Results: Length and order of GAD65 and IA2 sequences were critical for conservation of the conformational epitopes in the fusion protein. Among four chimera tested, only IA2 (606 -979) /GAD65 (1-585) retained wild-typelike folding of GAD65 and IA2 domains and yielded a stable protein after baculovirus expression. Reactivity of GAD65 antibody-and IA2 antibody-positive sera from patients newly diagnosed with insulin-dependent diabetes mellitus, from ICA-positive prediabetics, and
from ICA-positive first-degree relatives demonstrated conservation of the relevant autoreactive epitopes. The assay based on the in vitro translated fusion antigen had a sensitivity and specificity identical to those for detection of GAD65-and IA2-abs based on the two separate GAD65 and IA2 proteins. Conclusions: Autoantigens such as GAD65 and IA2 can be combined successfully in a fusion protein of similar immune reactivity. This allows simultaneous detection of GAD65-and IA2-abs in a one-step screening assay and cost-effective identification of positive individuals at risk of diabetes or at onset of disease.
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Insulin-dependent diabetes mellitus (IDDM) 4 is the result of a chronic autoimmune process characterized by circulating islet cell-specific autoantibodies (ICAs). These antibodies are detected in ϳ80% of individuals at diagnosis of IDDM and frequently appear years or even decades before the clinical onset of the disease (1 ) . Ongoing diabetes research is focusing on optimizing the prediction and prevention of insulin deficiency in IDDM. This will depend on large-scale screening for autoantibodies in relatives and, ultimately, in the general population.
Identification of autoantibody-positive individuals previously relied almost exclusively on the histochemical detection of ICAs on frozen sections of human pancreas (2, 3 ) . The usefulness of ICAs for routine screening of susceptible individuals or the general population is, however, limited by the technical difficulties, poor precision, and variable sensitivity of this test in different laboratories (4 -6 ) .
Two islet autoantibody specificities definitely represent major subfractions of ICAs: antibodies to the 65-kDa isoform of glutamic acid decarboxylase (GAD65-abs) (7, 8 ) the ␥-aminobutyric acid-synthesizing isoform of glutamate decarboxylase in human islets (9 ) , and antibodies to islet antigen-2 (IA2-abs) (10 ), a protein tyrosine phosphatase expressed in islet cells that has been described as a membrane protein composed of 979 amino acids (11 ) . Recent studies reported that screening for the two subspecificities of ICA, GAD65-abs and IA2-abs, may be an appropriate alternative for identification of positive subjects; however, the cost of using two specificities, instead of one, must be considered. To date, the distinction of GAD65-abs from IA2c-abs has been of no further therapeutic consequence for diagnosis of IDDM, and screening for autoantibody-positive individuals at risk in the general population would profit from easy one-step identification of both antibody markers.
We therefore aimed to design GAD65/IA2 fusion proteins suitable for simultaneous detection of GAD65-and IA2-abs. Because of one-step production, purification, and quantification, the ideal fusion protein could save time, money, and labor compared with separate testing of different antibody markers and could provide a reasonable target for a screening step, allowing cost-effective combined detection of GAD65-and IA2-abs.
Materials and Methods human sera
Sera were obtained with informed consent in accordance with the principles of the Declaration of Helsinki. Samples were collected from 101 patients at clinical onset of IDDM (34 females and 67 males; age range, 1-73 years; median age, 35 years) diagnosed according to WHO criteria (12 ) and from 245 healthy controls (155 females and 90 males; age range, 7-55 years; median age, 17 years). Patients were attending our hospital after onset of clinical symptoms and had Ͻ4 days of insulin treatment before serum samples were taken. Sera from 15 ICA-positive prediabetics (6 females and 9 males; age range, 3-13 years; median age, 9 years) and from 8 ICA-positive first-degree relatives (4 females and 4 males; age range, 3-12 years; median age, 6 years) were selected from a cohort of first-degree relatives from patients with IDDM. Forty-four reference sera from patients with type 1 diabetes were selected according to their reactivity to GAD65 but not IA2 (n ϭ 14), to IA2 but not GAD65 (n ϭ 15), and to both GAD65 and IA2 (n ϭ 15).
monoclonal antibodies
The human monoclonal ICAs (MICAs) 1-10, derived from ICA-positive patients newly diagnosed with type 1 diabetes, have been described elsewhere (8, (13) (14) (15) (16) . MICA 5 was not included in this study because it is an IgG 3 antibody that does not bind to protein A-Sepharose. The GAD65-specific mouse monoclonal antibody GAD-6 (17 ) was derived from the Developmental Studies Hybridoma Bank, and an IA2-specific mouse monoclonal antibody, 76F4B, was kindly provided by E. Bonifacio, Milan, Italy.
construction of chimeric gad65/ia2c molecules For construction of the chimera GAD65 /IA2 (606 -979) , a NotI restriction site was introduced by PCR at amino acid 585 of GAD65, eliminating the stop codon. A second PCR fragment [IA2 (606 -979) ] was generated with the restriction sites NotI at the 5Ј end and EcoRI at the 3Ј end. A pVL1393 vector (PharMingen) containing full-length GAD65 cDNA was cut with StuI and EcoRI and ligated with both PCR fragments in one step.
The second chimera, IA2c (606 -979) /GAD65 , was designed by generation of an IA2c PCR fragment (encoding amino acids 606 -979) with restriction sites NcoI and XhoI at the 5Ј and 3Ј ends, respectively. A GAD65 PCR fragment (1-585) with primers inserting restriction sites for XhoI (5Ј) and SacI (3Ј) was amplified. Both PCR fragments were cloned into the NcoI and SacI sites of pSP64poly(A) vector.
The third chimera, GAD65 (234 -585) /IA2 (606 -979) , was assembled first by generating a GAD65 PCR fragment (coding for amino acids 234 -442) with the restriction sites BamHI at the 5Ј end and StuI at the 3Ј end. The pVL1393 vector, which encodes for the chimera GAD65 (1-585) / IA2 (606 -979) , and the described GAD65 PCR fragment were cut with BamHI and StuI and ligated to obtain the final construct. Because of the cloning strategy, two additional glycine residues were generated between the residues of GAD65 and IA2.
The last chimera, IA2 (606 -979) /GAD65 (244 -585) , was constructed first by generating an IA2 PCR fragment (coding for amino acids 606 -979) with additional XmaI and NarI restriction sites at the 5Ј and 3Ј ends, respectively. The IA2 PCR fragment and a pSVSport1 vector, which included full-length GAD65 cDNA, were cut with XmaI and NarI and fused together by ligation. A leucine and a glutamic acid residue were generated by this cloning procedure between the two protein fragments. All plasmid constructs were verified by DNA sequence analysis.
autoradiography of recombinant proteins
Aliquots of the in vitro translated [
35 S]methionine-labeled chimeric proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 8% polyacrylamide gels. The gels were fixed with 400 mL/L methanol-100 mL/L glacial acetic acid before being dried under reduced pressure and exposed to x-ray films at Ϫ80°C for 1 day or longer.
ria for detection of gad65-ab and ia2c-ab GAD65-and IA2c-abs in sera were assessed by RIA as described previously (18 ) . In brief, 2.5 L of the sample Clinical Chemistry 47, No. 5, 2001 was incubated overnight with 35 S-labeled GAD65, IA2c, or IA2c/GAD65 fusion proteins and immunoprecipitated with protein A-Sepharose (Pharmacia). Sepharose-bound immune complexes were washed in a membrane-bottomed microtiter plate and transferred to scintillation vials, and the cpm were determined by a beta counter (Wallac, Pharmacia). MICA 3 was used as the calibrator for GAD65-abs, and an IA2-ab ϩ /GAD65-ab Ϫ reference serum of a patient newly diagnosed with IDDM was selected as the calibrator for IA2-abs. When GAD65-and IA2-abs were determined in the same test, 2.5 L of both MICA 3 and the IA2 reference serum were applied (combined calibrator). At the first Combined Autoantibody Workshop in 1995 (19 ) , the GAD65-ab RIA had a sensitivity of 70% [95% confidence interval (95% CI), 56 -83%] and a specificity of 100% (95% CI, 96 -100%). At the IDS Proficiency Workshop 2000, our RIA with IA2c (606 -979) /GAD65 achieved a sensitivity of 92% (95% CI, 81-98%) and a specificity of 98% (95% CI, 89 -100%) when we applied our in-house 4% assay cutoff according to ROC analysis.
expression of fusion proteins in Sf9-insect cells
In vivo expression of the two fusion protein variants GAD65 (1- was performed using the baculovirus expression system (20, 21 ) .
immunoblotting Sf9-insect cell lysate was prepared at various time points after infection, and the supernatant of a 100 000g centrifugation was separated by SDS-PAGE. Proteins were transferred to nitrocellulose (Bio-Rad) (22 ) before immunostaining with a polyclonal rabbit anti-GAD65-ab or anti-IA2-ab (1:1000 dilution) and alkaline phosphataseconjugated anti-rabbit IgG antibody (1:20 000 dilution; Dianova). Bound antibodies were visualized on nitrocellulose, using an alkaline phosphatase substrate solution of Nitro Blue Tetrazolium/5-bromo-4-chloro-3-indolyl phosphate [Sigma; 66 and 33 L, respectively, in 10 mL of 60 mmol/L Tris-HCl (pH 7.5), 325 mmol/L NaCl, 0.5 mL/L Tween 20].
roc analysis
Sensitivity/specificity pairs were calculated by varying the decision threshold values over the entire range of results (23, 24 ) . Sensitivity (the true-positive fraction) was calculated with samples derived from 101 patients at clinical onset of IDDM. The specificity (the true-negative fraction) was calculated from 246 healthy individuals. The experimental cutoff for each assay was determined by calculating the decision threshold as follows: for each given threshold, the values for sensitivity and specificity were added, and the value at the maximal sum was used as the experimental cutoff. Test results above binding of the undiluted calibrators (100% binding) and the linear range of the calibration curve were set to 100%.
statistical analysis
Correlation and the agreement between the results obtained with the assay using a GAD65/IA2 fusion protein and the RIA for combined detection of GAD65-and IA2-abs (18 ) based on separate antigens were examined with the method of Bland and Altman (25, 26 ) . In short, this method uses a plot of the difference between the assays compared against their mean. This kind of plot allows investigation of any possible relationship between the measurement error and the true value. The mean of the two measurements is the best estimate for the measurement error. For all statistical methods, the Statistical Package for Social Science (SPSS) was used.
Results

expression of the chimeric gad65/ia2 proteins by in vitro transcription/translation
Four different chimeric proteins combining full-length GAD65 or truncated GAD65 with IA2c, the intracellular part of IA2 (residues 606 -979), were designed and constructed (Fig. 1) . All four chimeric GAD65/IA2c proteins were successfully expressed by in vitro transcription and translation in a reticulocyte lysate system. The estimated molecular masses of the fusion proteins were 108 and 72 kDa. However, analysis of the proteins by SDS-PAGE revealed molecular masses of ϳ97 and 74 kDa, respectively (data not shown). Few additional bands were indicative for low-level protein degradation or prematurely stopped translation. Protein expression was monitored over a time course of 31-53 h to determine the optimum protein expression after infection with recombinant baculovirus. Staining was performed with a polyclonal rabbit anti-IA2c-ab or rabbit anti-GAD65-ab, as indicated. Blots were incubated with alkaline phosphatase-conjugated secondary antibodies and developed by an alkaline phosphatase enzyme color assay. Lanes 1 and 6, 31 h; lanes 2 and 7, 47 h; lanes 3 and 8, 49 h; lanes 4 and 9, 51 h; lanes 5 and 10, 53 h after infection. Filled bars indicate GAD65 ; open bars indicate IA2c (606 -979) .
epitope conservation in the chimeric gad65/ia2c proteins Correct folding of the subunits in chimeric proteins is crucial for preservation of epitope recognition by diseaseassociated autoantibodies. The conformational integrity of the GAD65 domains was checked by RIA using the diabetes-related human monoclonal GAD65 antibodies MICA 1-10. These antibodies define nine distinct conformational epitopes in GAD65, seven of which reside between amino acids 240 and 585 of GAD65 (14, 16, 27 ) . To monitor the conformation of IA2c, one mouse monoclonal antibody (76F4B), which recognizes an epitope of the cytoplasmic part of IA2 that is located near the membrane, was available. Therefore, sera from two IA2c-ab ϩ , GAD65-ab Ϫ patients were included, one of which was directed exclusively to the COOH terminus of IA2c (amino acids 771-979), whereas the other recognized several epitopes. Compared with wild-type GAD65 (Fig. 1A) , the reactivities of MICA 1-10 were almost completely lost in the two chimeras GAD65 (234 -585) /IA2c (606 -979) (Fig. 1C) and IA2c (606 -979) /GAD65 (244 -585) (Fig. 1D) , although, according to the GAD65 residues present in the chimeras, all MICAs except MICA 8 and MICA 9 were expected to react (14 ) . Recognition of the IA2c domain was conserved in both constructs, but decreased reactivity was observed compared with the IA2c molecule alone. In the fusion protein GAD65 (1-585) /IA2c (606 -979) (Fig. 1E) , all MICA epitopes except MICA 2 and MICA 7 were conserved. Only for MICA 3 and MICA 10, however, was binding as high as with the wild-type GAD65 protein. Again, IA2c-ab reactivity was reduced approximately twofold compared with the IA2c molecule (Fig. 1B) . Within chimera IA2c (606 -979) /GAD65 , all nine tested MICA epitopes and the IA2c reactivity were conserved with no significant loss of binding compared with wild-type GAD65 and IA2c (compare panels A, B, and F in Fig. 1) . Thus, the length of the GAD65 fragment was crucial for its correct folding in the fusion protein. The wild-type conformation of GAD65 was preserved only in the IA2c (606 -979) /GAD65 chimera, where the COOH terminus of GAD65 was freely accessible. In contrast, IA2c tolerated well a connection of its C-terminal end to GAD65.
order of gad65 and ia2c in fusion proteins is relevant for in vivo expression
Recombinant baculoviruses were produced that coded for the two fusion protein variants GAD65 (1-585) /IA2c (606 -979) and IA2c (606 -979) /GAD65 . Expression studies over a time interval of 31-53 h after infection of Sf9-insect cells revealed that only the IA2c/GAD65 chimera with GAD65 at the COOH terminus was expressed as a stable protein (Fig. 2) . This indicated that the orientation of the two protein fragments GAD65 and IA2c within the fusion protein is crucial for stable expression of correctly folded GAD65 and IA2c domains in Sf9-insect cells.
preserved reactivity of sera from patients and individuals at risk
The immune reactivity of GAD65-ab ϩ and/or IA2c-ab ϩ IDDM sera and of sera from ICA-positive prediabetics with in vitro expressed IA2c (606 -979) /GAD65 was analyzed by RIA. All 14 of the monospecific GAD65-ab ϩ / Fig. 4 . Quantitative correlation analysis.
The correlation and agreement between the assays detecting GAD65-and IA2c-abs based on the fusion protein or on the separate antigens were assessed by a method described previously by Bland and Altman (27, 28 ) . Difference in the percentage of antibody binding (GAD65/IA2c fusion protein minus combined detection of GAD65-abs and IA2c-abs on separate antigens) is shown on the y axis. Mean relative antibody binding measured by the two methods is shown on the x axis (r ϭ 0.99; R 2 ϭ 0.98; P Ͻ0.00001; mean Ϯ SD, 0.37 Ϯ 4.68). Test results above binding of the undiluted calibrator (100% binding) and the linear range of the calibration curve were set to 100%. The data revealed that both methods were not only highly related but also showed good agreement, especially near the cutoff (binding, 4 -30%). Reactivities of 101 sera from patients newly diagnosed with IDDM (A), 15 sera from ICA-positive prediabetics (B), and 8 sera of ICA-positive first-degree relatives (C) were assessed in the separate GAD65 and IA2c RIAs and compared with results obtained with the fusion protein IA2c (606 -979) /GAD65 . Five sera (four patients and one ICA-positive prediabetic subject) positive with the fusion protein did not give positive results for the GAD65-and IA2c-abs separately. Bispecific sera with low concentrations of both GAD65-and IA2c-abs may account for the slightly better performance of combined testing based on the fusion protein.
IA2c-ab
Ϫ sera, all 15 GAD65-ab Ϫ /IA2c-ab ϩ sera, and all 15 bispecific GAD65-ab ϩ /IA2c-ab ϩ sera bound to chimera IA2c (606 -979) /GAD65 . In addition, all 15 sera from ICA-positive prediabetics recognized the IA2c/ GAD65 fusion protein (Fig. 3) . This demonstrated that the relevant IDDM-and prediabetes-associated immune reactivity was preserved in this fusion protein.
equal performance of ia2c (606 -979) /gad65 and the separate antigens gad65 and ia2c in ria
To compare the performance of the GAD65/IA2c fusion protein with the separate antigens in detection of GAD65-and IA2c-abs, we analyzed sera from 101 newly diagnosed IDDM patients and from 245 control subjects by RIA. The threshold for discrimination of positive from negative sera was then selected by different means. In ROC plot analysis, the optimal cutoff was at 4% antibody binding for both assays. When the 99th percentile or maximum specificity was selected, the cutoff changed accordingly ( Table 1) . Irrespective of the mode of cutoff selection, the fusion protein gave equal or slightly superior values for sensitivity and specificity compared with a test in which the separate antigens were used (Table 1) . To quantitatively approach the correlation and agreement between the antibody assays, we used a method described previously by Bland and Altman (25, 26 ) . The data shown for the 101 patients' sera (Fig. 4) revealed that the two test methods were not only highly related (r ϭ 0.99; R 2 ϭ 0.98; P Ͻ0.00001) but also showed good agreement, especially near the cutoff (4 -30% autoantibody binding). The mean (0.37) indicated that the assay using the GAD65/IA2c fusion protein measured on average slightly higher test scores than the combined detection of GAD65-abs and IA2c-abs based on separate antigens. Thus, the performance of the RIA based on the IA2c (606 -979) /GAD65 fusion protein was almost indistinguishable from that of combined or separate testing of GAD65-and IA2c-abs. diagnostic power in patients, prediabetics, and individuals at risk Sera from 15 prediabetic individuals and 8 ICA-positive sera selected from 62 first-degree relatives were subjected to analysis of GAD65-abs and IA2c-abs by tests based on the separate antigens and the fusion protein. Independent of the mode of cutoff selection, the fusion protein assay detected more IDDM sera (Fig. 5A ) and ICA-positive sera from prediabetics and from first-degree relatives (Fig. 5, B and C). Separate testing missed four sera from patients with IDDM and one serum derived from a prediabetic individual 56 months before diagnosis of IDDM. Sera with low concentrations of GAD65-and IA2c-abs just below the assay cutoff of the separate tests may account for this superior performance of the fusion protein assay.
The fusion protein assay thus improved detection of patients' sera compared with assays based on the separate antigens. Hence it can be recommended for further studies on risk assessment of IDDM.
Discussion
Detection of autoantibodies has profoundly influenced our advancing knowledge in clinical immunology and immunopathology. Organ-specific and systemic autoimmune diseases often are characterized by circulating autoantibodies directed to several distinct target antigens, which become more and more defined on the molecular level with the consequence that the number of autoantibody tests steadily increases. In all cases in which the exact antigen specificity in the target tissue is of no direct diagnostic or clinical consequence, economic testing dictates a reduction in the number of markers to be determined. Instead of focusing, however, on only one of several major, partially overlapping antibody specificities, such as is done frequently with GAD65-abs in IDDM, we here present a strategy to combine the immunodominant regions of several autoantigens in a new molecule. To our knowledge, this is the first report describing generation and testing of fusion proteins of autoantigens leading to a successful one-step detection of two autoantibody specificities. One of the new molecules we designed retained the wild-type-like conformation of all crucial domains of the parent molecules. A RIA based on this fusion protein performed identically or slightly superior to RIAs based on the separate antigens. Testing of fusion proteins is, therefore, a superior alternative for economic testing of samples without a need to disclaim major reactivities.
Among four distinct GAD65/IA2c fusion proteins that included various lengths and opposite orientations of the GAD65 and IA2c domains, only chimera IA2c (606 -979) / GAD65 showed complete epitope conservation in the GAD65 and IA2c domains according to binding studies with 10 monoclonal antibodies and sera specific for GAD65 or IA2c, respectively (Fig. 1) . IA2c (606 -979) / GAD65 fusion protein, but none of the other tested chimera, performed almost indistinguishably from the separate GAD65 and IA2c proteins in RIAs in which sera from patients with IDDM and from ICA-positive prediabetics, ICA-positive first-degree relatives, and control subject were analyzed (Figs. 3 and 5 ). IA2c (606 -979) / GAD65 protein also retained the wild-type conformation of the GAD65 and IA2c domains when expressed by recombinant baculoviruses in insect cells. The fusion protein described here may be especially useful in increasing the efficiency of screening for autoantibody-positive subjects in risk groups or in the general population with the purpose of preparing prevention studies.
Instead of testing all sera twice in two distinct assays, we suggest a new two-step strategy. The first step, based on the fusion protein assay, would identify the 1-3% expected positive samples; thus, only those samples will have to undergo thorough risk analysis in the second step, which involves looking for individual antibody markers (28 ) , for epitope recognition (15 ) , or for subclass distribution (29 ) , which could further refine risk assessment. More thorough, labor-intensive, and expensive testing would thus be confined to only 1-3% of the total samples.
In addition to GAD65-abs and IA2c-abs, antibody specificities such as islet cell, insulin, and proinsulin autoantibodies have been applied for the prediction of IDDM. We did not include insulin or proinsulin protein domains in our fusion proteins because studies on firstdegree relatives (30, 31 ) and in a population of schoolchildren showed that their predictive value is below that of GAD65-abs and IA2c-abs and did not enhance prediction in a family study (31 ) . Reduction of islet antibody reactivities to only the major immunogenic parts of the GAD65 and the IA2 molecules was evaluated in this study. It was successful only for the intracellular part of IA2, which attracted most of the IA2-ab reactivity (32, 33 ) . Although most of the autoreactive epitopes of GAD65 are located within the middle and the C-terminal regions of GAD65 (amino acids 245-585) (27, 34 ) , truncated GAD65 lost almost all of its autoreactive epitopes when it was integrated in a chimeric protein with IA2c (Fig. 1, C and  D) . Thus, the length of GAD65 was important for its correct folding, and a free GAD65 COOH terminus was required for stable expression and full preservation of epitope recognition.
The close correlation between combined GAD65-ab and IA2c-ab detection based on the separate antigens and on our fusion protein IA2c (606 -979) /GAD65 suggests this molecule as an ideal tool for economical diagnostic testing and population screening for prediction of IDDM. To confirm the usefulness of this combi-assay, its performance now needs to be compared with that of separate assays on a large unselected group of subjects.
In conclusion, fusion proteins combined from several autoantigens can reduce the effort for analysis of several autoantibody specificities to one test, allowing combined analysis of the desired markers. Thus, diagnosis, risk assessment, or prediction of autoimmune diseases can profit from this efficient and cost-effective strategy, especially in cases involving large sample collections with a low prevalence of positive sera and in autoimmune disorders in which the presence of target-specific antibodies, rather than their exact specificity, is of therapeutic consequence.
